Switzerland's Clariant Q3 sales beat on higher prices, EBITDA misses on cost pressure

By Reuters News


Overview

  • Switzerland specialty chemical firm's Q3 sales rose 5.6% in local currency, beating analyst expectations

  • Q3 adjusted EBITDA missed analyst expectations as margins fell on cost phasing and mix effects

  • Company maintained 2026 guidance, citing strong order book and cost-saving progress


Outlook

  • Clariant maintains 2026 guidance, expecting sales in local currency to be around flat

  • Company expects 2026 EBITDA margin before exceptional items of around 18%

  • Clariant expects free cash flow conversion above 45% in 2026


Result Drivers

  • PRICING GAINS - Co said sales growth was driven by higher prices across all business units in response to inflationary raw material, energy and logistics costs

  • MIDDLE EAST IMPACT - Co said Catalysts volumes were negatively affected by the ongoing conflict in the Middle East, leading customers to delay orders

  • MIX AND COST EFFECTS - Co said margin decline was due to less favorable mix and volatile raw materials affecting costs and inventory valuation in Care Chemicals and Catalysts


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

CHF 968.8 mln

CHF 925.14 mln (7 Analysts)

Q3 Adjusted EBITDA

Miss

CHF 151.5 mln

CHF 161.20 mln (5 Analysts)

Q3 EBITDA

CHF 144 mln

Q3 EBITDA Margin

14.9%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

  • The average consensus recommendation for the specialty chemicals peer group is "buy"

  • Wall Street's median 12-month price target for Clariant AG is CHF10.75, about 3% above its November 2 closing price of CHF10.44

  • The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 12 three months ago


Reuters Recommended Reads

  • Nov 2 - Chemours Q3 adjusted profit misses estimates despite titanium pricing gains

  • Nov 2 - Huntsman Q3 revenue beats estimates on higher sales volumes

  • Nov 3 - Evonik Q3 core profit misses estimates, sees earnings at upper end of guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.